Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 42799-922

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 42799-922). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Edenbridge Pharmaceuticals Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg 30 (10 mg 30 Count)

FDA Label Image

10mg 500 (10 mg 500 Count)

This is a medication called Bisoprolol Fumarate and Hydrochlorothiazide in tablet form with a strength of 10 mg and 6.25 mg respectively. This medicine is available in a bottle containing 500 tablets.*

FDA Label Image

10mg 100ct

FDA Label Image

25 100 (25 mg 100 Count)

FDA Label Image

25mg 30 (25 mg 30 Count)

Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP are a medication used to treat high blood pressure. Each tablet contains 25mg of bisoprolol fumarate and 625mg of hydrochlorothiazide. The bottle contains 30 tablets. The text also includes some gibberish characters that may be a result of an error in the process.*

FDA Label Image

25 500 (25 mg 500 Count)

This is a label for a bottle of Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP with a strength of 25mg/6.25mg and a quantity of 500 tablets.*

FDA Label Image

5mg 100 (5 mg 100 Count)

The text contains the names of two drugs, Bisoprolol Fumarate and Hydrochlorothiazide, in tablet form with a dose of 5mg of Bisoprolol Fumarate and 625mg of Hydrochlorothiazide.*

FDA Label Image

5mg 30 (5 mg 30 Count)

This is a prescription pharmaceutical with the name Bisoprolol Fumarate and Hydrochlorothiazide. It is available in tablet form with dosages of 5mg and 25mg.*

FDA Label Image

5mg 500 (5 mg 500 Count)

FDA Label Image

Biso Api Structure (Api Pic New1)

FDA Label Image

Hctz Api Structure (Api Pic New2)

FDA Label Image

Table 1 (Table 1 New)

The text is reporting results of a study on Sitting Systolic/Diastolic Blood Pressure (BP) and Heart Rate (HR) reduction after 3.4 weeks of treatment with different drugs. The table presents the study results for Placebo, BSH6.25, H625mg, B3/H62smg, and BI0/H625 drugs in Study 1 and Study 2. The study reports the mean decrease (A) for BP and HR and the observed mean change from baseline minus placebo.*

FDA Label Image

Table-3 (Table 3 New)

This is a table describing the adverse experiences of patients in a clinical trial. It lists various body systems and corresponding adverse experiences, such as chest pain and cough. The table also indicates the percentage of patients who experienced drug-related adverse effects.*

FDA Label Image

Table-2 (Table New 2)

This appears to be a table containing data on serum potassium levels in a study conducted in the US. The study was likely placebo-controlled, but there is not enough information to determine the specifics. The table shows mean change in serum potassium levels measured in mEq/L between 2004 and 7011 for both the Placebo and the treatment group ("B10)"). It also indicates the percentage of participants who experienced hypokalemia (low potassium levels) in each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.